Cancer—A Major Cardiac Comorbidity With Implications on Cardiovascular Metabolism

Daniel Finke1,2,3, Markus B. Heckmann1,2,3, Norbert Frey2,3 and Lorenz H. Lehmann1,2,3,4*

1 Cardio-Oncology Unit, University Hospital Heidelberg, Heidelberg, Germany, 2 Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany, 3 DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany, 4 Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany

Cardiovascular diseases have multifactorial causes. Classical cardiovascular risk factors, such as arterial hypertension, smoking, hyperlipidemia, and diabetes associate with the development of vascular stenoses and coronary heart disease. Further comorbidities and its impact on cardiovascular metabolism have gotten more attention recently. Thus, also cancer biology may affect the heart, apart from cardiotoxic side effects of chemotherapies. Cancer is a systemic disease which primarily leads to metabolic alterations within the tumor. An emerging number of preclinical and clinical studies focuses on the interaction between cancer and a maladaptive crosstalk to the heart. Cachexia and sarcopenia can have dramatic consequences for many organ functions, including cardiac wasting and heart failure. These complications significantly increase mortality and morbidity of heart failure and cancer patients. There are concurrent metabolic changes in fatty acid oxidation (FAO) and glucose utilization in heart failure as well as in cancer, involving central molecular regulators, such as PGC-1α. Further, specific inflammatory cytokines (IL-1β, IL-6, TNF-α, INF-β), non-inflammatory cytokines (myostatin, SerpinA3, Ataxin-10) and circulating metabolites (D2-HG) may mediate a direct and maladaptive crosstalk of both diseases. Additionally, cancer therapies, such as anthracyclines and angiogenesis inhibitors target common metabolic mechanisms in cardiomyocytes and malignant cells. This review focuses on cardiovascular, cancerous, and cancer therapy-associated alterations on the systemic and cardiac metabolic state.

Keywords: cardio-oncology, cancer metabolism, cardiac metabolism, cytokines, second messenger, metabolic shift, inflammation, heart failure

INTRODUCTION

Currently, a percentage of 18% of cancer patients are seen with cardiovascular comorbidities in large population-based studies. The highest rates are observed in prostate cancer patients (36.5%) or patients with endometrial carcinoma (29.2%). Cardiovascular complications range from stroke to arrhythmias, coronary heart disease (CHD), cardiomyopathy, heart failure (HF), or valvular diseases (Liu et al., 2019). Death due to cardiovascular complications is mostly seen
in patients suffering from prostate cancer, breast cancer, lung cancer or urinary bladder cancer (Sturgeon et al., 2019).

Cardiovascular diseases itself, such as CHD and HF, are mostly attributed to the occurrence of cardiovascular risk factors (e.g., arterial hypertension, diabetes, smoking, age, hypercholesterinemia, and adiposity) or predisposing genetic factors (Jacoby and McKenna, 2012; McPherson and Tybjaerg-Hansen, 2016; Piepoli et al., 2016).

These are not solely risk factors for cardiovascular diseases, but also increase the risk of cancer (Freedman et al., 2011; Stocks et al., 2012; Koene et al., 2016; Lauby-Secretan et al., 2016). Recently, the interdisciplinary field of cardio-oncology focuses on the interaction of both diseases in terms of the shared risk profile, but also in terms of a direct interaction between the two systemic diseases (Cardinale, 1996).

Commonly known are adverse effects of cancer therapy (Tilemann et al., 2018). Therefore, the cardiotoxic cardiomyopathy is the initial interdisciplinary focus of cardio-oncology (Cardinale et al., 2015; Rassaf et al., 2020). The field shifts to a paradigm of malignant diseases itself as a risk factor for the development of cardiovascular complications and vice versa (Demers et al., 2012; Gernaat et al., 2018). Currently, efforts are made to describe the differential role of HF and CHD in the progression of cancer (Rinde et al., 2017; Koelwyn et al., 2020; Lau et al., 2021).

The molecular interaction of heart disease and cancer have multiple layers. The development of inflammatory processes, either of cardiac or malignant origin, is one factor (Anker and von Haefling, 2004; Frantz and Nahrendorf, 2014; Noy and Pollard, 2014; Duan and Luo, 2021). Increased oxidative stress is another mechanism which is discussed to connect both diseases (Kanai et al., 2001; Chan et al., 2017). Additionally, different cytokines and paracrine mechanisms mediate a direct crosstalk (Quail and Joyce, 2013; Bang et al., 2015; Olson et al., 2017).

Besides, metabolic disorders are linked to cancer and HF (Kalstaedt et al., 2018). In fact, a reprogrammed metabolism is essential for tumor growth, including an increased uptake of glucose and amino acids, different use of metabolic intermediates and alterations in gene expression or microenvironmental interactions (Pavlova and Thompson, 2016). Anaerobic glycolysis and lactate production is one of the central mechanisms in tumor metabolism. This includes a dysregulation of key enzymes in different glycolysis pathways.

In heart disease, various metabolic adaptations, such as switch from lipid to glucose metabolism in HF (Murashige et al., 2020) and diabetic cardiomyopathy, are associated with an increased myocardial stiffness (van Heerebeek et al., 2008) and altered Ca\(^{2+}\) -handling (Lambert et al., 2015; Seferovic and Paulus, 2015). There are concurrent adaptations in glucose metabolism, including glycolysis and its side pathways, in cancer and HF.

Nevertheless, the direct interaction of cardiac and cancer metabolism is an emerging field which needs further evaluation. The oncometabolite D-2-hydroxyglutarate (D2-HG) is one example of a primary metabolic interaction of cancer and the heart (Kalstaedt et al., 2016; Kattih et al., 2021).

This review focuses on the available data of concurrent and causative metabolic events in cardiac disease and cancer and its impact on cardiac dysfunction and cancer progression, respectively.

**CANCER THERAPIES AND CANCER ITSELF MAY INFLUENCE THE CARDIAC FUNCTION**

Initially, the cardiotoxic effects of chemotherapies are seen as the primary connection between cardiac function and cancer. Especially, a drop in left ventricular function is associated with the administration of anthracyclines (Zambetti et al., 2001). The majority of studies that deal with cardiotoxicity has concentrated on breast cancer patients (Levis et al., 2017). This may be due to the broad usage of cardiotoxic anthracyclines but also to a favorable outcome with the possibility of larger observation intervals. Later, also further drugs, such as trastuzumab, were linked to cardiotoxicity (Slamon et al., 2001; Ozcikli et al., 2002).

Cardiotoxicity is initially defined as a declined left ventricular function. More recent studies describe changes in diastolic function or cardiac deformation (strain measurements) (Bird and Swain, 2008; Serrano et al., 2015). Also in patient cohorts that are not restricted to breast cancer patients, cardiac biomarkers (including N-terminal pro B-type natriuretic peptide (NT-proBNP), mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-pro-ET1), and high sensitivity cardiac troponin T (hs-cTnT)) are found to be associated with cancer and cancer therapies. In cardiac disease, the natriuretic peptides are generally parameters for heart failure and pressure overload, hs-cTnT is primarily related to cardiac cell death (Pavo et al., 2015). Patients with elevated levels of NT-proBNP and hs-cTnT often show a preserved ejection fraction (Finke et al., 2021).

Apart from these observations, no studies have dissected HF with reduced (HFpreEF) and preserved ejection fraction (HFpEF) in terms of chemotherapies or the neoplastic disease itself. A recent study, the CARDIOTOX registry, suggests a new definition of cardiotoxicity. Here, the systolic function and cardiac biomarkers are taken into account, neither including the diastolic function nor strain measurements (Lopez-Sendon et al., 2020).

Beyond the effects of chemotherapies, there is a direct crosstalk between cancer and the heart. On the one hand, HF may lead to incident cancer and vice versa cancer itself may lead to cardiac dysfunction (Meijers and de Boer, 2019). A large population-based analysis of patients with myocardial infarction (MI) for example finds that patients with MI had higher incidences of cancer than comparable patients without MI. The highest rates are observed for colorectal cancer, prostatic cancer and lung cancer (Rinde et al., 2017). In addition, cancer patients are reported to have higher rates of cardiac complications (Sturgeon et al., 2019). If those complications are based on the shared risk profiles, treatment-related effects or a direct interaction of the diseases is frankly difficult to dissect in a clinical setting. Molecular studies focus on specific alterations due to cancer itself and link them with adverse cardiac effects. Among those alterations, secreted and circulating molecules are found,
which may directly affect cardiac function. These molecules are an independent risk factor of cardiac dysfunction in cancer patients, apart from cancer therapies (see Table 1).

**CANCER—A SYSTEMIC DISEASE—AFFECTS THE HEART**

Cancer is a *debilitating* disease. In many cases, cancer leads to cachexia based on alterations of metabolic pathways. Clinically, it results in fatigue, frailty and a reduced quality of life. Finally, the mortality rates of cancer patients are even higher due to cachexia (von Haehling and Anker, 2014).

One manifestation of cachexia is skeletal muscle wasting, which is one of the main causes for the mentioned detrimental effects. The loss of muscle causes serious metabolic alterations. In skeletal muscles, high rates of protein degradation result in amino acid accumulation. These amino acids serve as substrates for gluconeogenesis in the liver. The elevated glucose levels and glutamine, a released amino acid from the muscles, serve as energy supply for the neoplastic tissues and basis for protein or DNA synthesis (Clunton et al., 2017). The high energy demand of the tumor results in high levels of circulating lactate, which in turn is used for gluconeogenesis in the liver. This is the basis for the energy-inefficient Cori cycle. Adipose tissue is wasted during this process. Triacylglycerols (TAGs) are lipolyzed to glycerol and non-essential fatty-acids (NEFAs), which again are used for gluconeogenesis and energy supply for the tumor, respectively (Argiles et al., 2014).

Preclinical data indicates that cardiac muscle wasting is associated with cancer cachexia. In a hepatoma rat model, the authors observe left ventricular (LV) dysfunction, fibrotic cardiac remodeling and increased mortality (Springer et al., 2014). Accordingly, in patients with tumor cachexia, bodyweight loss and muscular atrophy is associated with loss of cardiac weight (Barkhudaryan et al., 2017). Patients with Hodgkin lymphoma show an increase in cardiac glucose uptake, supporting the hypothesis of a direct metabolic re-programming in certain entities of cancer (Heckmann et al., 2019). In turn, HF is associated with loss of lean tissue mass and reduced exercise capacity, also because of a reduction of skeletal muscle mass (Strassburg et al., 2005). In addition, wasting is identified as an independent risk factor for mortality in HF patients (Anker et al., 1997b).

Trying to unravel the pathophysiology of wasting and its correlation with the cardiac function, several mechanisms have been identified. Malnutrition and malabsorption from the gut, inflammation and hormonal regulations are some mediating factors (von Haehling et al., 2007). All of these may be influenced by cancer and HF and vice versa.

**MALNUTRITION IN HEART FAILURE AND CANCER**

Cancer-associated malnutrition has multiple reasons. On the one hand, there are adverse effects of cancer treatment and local, obstructive effects of the tumor itself, which lead to a reduced food intake. On the other hand, HF may lead to bowel edema and impairments in gut perfusion. This, in turn, results in malabsorption as well (King et al., 1996). The gut microbiota is changed in HF patients, too (Tang et al., 2019). Pathogenic gut flora overgrowth, including Candida, Campylobacter, Shigella, Salmonella, and Yersinia enterocolitica, is present in HF patients in an observational study from Pasini et al. (2016). The authors are able to link the pathogenic populations to the severity of HF using the clinical New York Heart Association classification (Pasini et al., 2016).

Splanchnic congestion may lead to impaired intestinal barrier function and thereby to a systemic inflammatory response and cytokine release, which in turn may result in lean mass loss and cardiac muscle wasting (Aoyagi et al., 2015). Due to malabsorption and malnutrition, Cluster of differentiation 14 (CD14) levels are elevated in cachectic HF patients in line with increased levels of tumor necrosis factor alpha (TNF-α), indicating an endotoxin release with a concomitant inflammatory response (Anker et al., 1997a).

**THE ROLE OF AN INFLAMMATORY RESPONSE, ORIGINATED FROM THE HEART OR CANCER, AND ITS IMPLICATION IN METABOLIC DISORDERS**

The levels of inflammatory circulating factors, such as soluble tumor necrosis factor receptors (sTNF-Rs), soluble intercellular adhesion molecule-1 (sICAM-1), interleukine (IL)-6, lipopolysaccharide binding protein (LBP), and C-reactive protein (CRP) are associated with weight loss in patients with non-small-cell lung cancer (NSCLC) (Staal-van den Brekel et al., 1995). Elevated CRP levels and weight loss are seen in patients with a reduced physical function and prognosis. Weight loss as a single factor does not identify the patients at risk sufficiently (Fearon et al., 2006). Preclinical models are used to further understand the pathomechanism of an inflammatory response in cancer or the heart and its effect on metabolism.

Interferon-gamma (IFN-γ) producing Chinese Hamster Ovary cells (CHO-cells) are injected in mice and cause cachexia solely in the presence of IFN-γ and tumor cells. Inhibition of IFN-γ or the injection of non-IFN-γ producing cells do not result in a comparable degree of cachexia (Matthys et al., 1991a). In an animal model of lung cancer, IFN-γ is necessary for the development of tumor cachexia and is blocked by administration of anti-IFN-γ antibodies (Matthys et al., 1991b). Whether this is associated with an atrophy of cardiac muscle has not been investigated.

IFN-γ knockout (KO) mice do not show mitigated response to tumor-induced cachexia in a model of sarcoma in C57BL6 mice. This may indicate a tumor- and non-host-dependent mechanism of IFN-γ in cachexia. In turn, IL-6 KO animals show no tumor-associated cachexia (Cahlin et al., 2000). Anti-IL-6 antibodies are able to mitigate tumor cachexia in a mouse model of colon cancer (Strassmann et al., 1992). IL-6 transgenic mice show muscular atrophy of the gastrocnemius muscle (Tsujinaka et al., 1995).
| Factor | Metabolic disorder | Intervention | Cardiovascular studies | Cancer studies | Interdisciplinary studies |
|--------|-------------------|--------------|------------------------|---------------|--------------------------|
| **Inflammation** | | | | | |
| IFN-γ | Cachexia | Anti-IFN-γ antibodies | | Matthys et al., 1991a | |
| IL-6 | Cachexia | IL-6 KO animals | | Cahlin et al., 2000 | |
| | | Anti-IL-6 antibodies | | Strassmann et al., 1992 | |
| Muscular atrophy | IL-6 transgenic mice | | | | Tsujinaka et al., 1995 |
| Muscular atrophy | IL-6 injections | | | | Haddad et al., 2005 |
| TNF-α | Cachexia | Injection of TNF-α-producing CHO cells | | | |
| | Cachexia | Pharmacological inhibition of TNF-α | | Steffen et al., 2008 | |
| IL-1β | Cachexia | Injection of IL1-receptor antagonists | | | Strassmann et al., 1993 |
| **TGF-β signaling** | | Blockage of Activin ActRIIB pathway in C26 tumor-bearing mice | | Zhou et al., 2010 | |
| **Myokines** | | Cardiomyocyte-specific deletion of myostatin and use of a myostatin blocking antibody | | Heineke et al., 2010 | |
| Myostatin | Muscle wasting | Cardiomyocyte-specific deletion of myostatin and use of a myostatin blocking antibody | | Heineke et al., 2010 | |
| SerpinA3 | Tumor growth | miR/miR inhibitor transfection | | Meijers et al., 2018 | |
| **Cachexokines** | | | | | |
| Ataxin-10 | Cardiac atrophy | Tumor cell (MC38, C26, SW480) injection in mice, APC delta 580 mice | | Schafer et al., 2016 | |
| Insulin depletion | Cardiac wasting | Insulin supplementation | | Thackeray et al., 2017 | |
| **MicroRNAs** | | | | | |
| miR-145 | Cardiac fibrosis | miR-145 KO mice | | Zhao et al., 2015 | |
| | | miR/miR inhibitor transfection | | | |
| miR-1 | Elevated in Mi after LAD ligation | LAD ligation | | D’Alessandra et al., 2010 | |
| miR-133a/b | Elevated in Mi after LAD ligation | miR transfection | | Liu et al., 2017 | |
| miR-206a | AV blockage/DCM | miR-206a Tg/KO mice | | Callis et al., 2009 | |
| | Elevated in Mi after LAD ligation | miR transfection | | Qin et al., 2013 | |
| | Elevated in Mi after LAD ligation | miR transfection | | Li et al., 2014 | |
| **Metabolism** | | Heart failure and mitochondrial dysfunction | | Wende et al., 2015 | |
| Akt | Akt transgenic mice, constative active and inducible | | | | |
| Enhanced glucose metabolism, GLUT-1 expression, HK activity, HK-mitochondria interaction | Inducible Akt-transgenic mouse hepatoma cells Akt-1 KO, Akt-1/2 dKO | | | Barthel et al., 1999 | Majewski et al., 2004 |
| PGC-1α | Heart failure | PGC-1α KO mice | | Arany et al., 2006 | |
| | PGC-1α KO mice | | | Patten et al., 2012 | |
| Apoptosis | Pancreatic Cancer Stem Cells/Metformin/MYC expression | Breasts cancer cell lines/ siRNA treatment | | Sancho et al., 2015 | |
| Glycolytic flux and poor prognosis in breast cancer treatment | | | | McGuirk et al., 2013 | |
| O-GlcNAc | Cardiac Hypertrophy | Db/db mice | | Marsh et al., 2011 | |
| | Heart failure | Db/db mice, STZ injections, HDAC4 KO mice | | Kronlage et al., 2019 | |

(Continued)
Circulating metabolites

**D2-HG**

**Circulating metabolites**

- **Alterations in cardiac glucose utilization and epigenetic repression**
  - IDH2{	extsuperscript{R140Q}}-mutant mice

**Carnitocytotoxicity**

- **AML patients with IDH1/2, IPS derived cardiomyocytes**

**TABLE 1** (Continued)

| Factor | Metabolic disorder | Intervention | Cardiovascular studies | Cancer studies | Interdisciplinary studies |
|--------|--------------------|--------------|------------------------|----------------|--------------------------|
| Transient CMP | HDAC4 KO mice, STIM1/2 dKO mice | | Lehmann et al., 2018 | | |
| Glycolytic flux/apoptosis | Breast cancer cell line/OGT-shRNA transfections | | | Ferrer et al., 2014 |
| | Pancreas duct epithelial cells/OGT-shRNA transfections | | | Ma et al., 2013 |
| Tumor growth | Xenograft models with shOGT | | | Caldwell et al., 2010 |

Apart from inflammation, other factors are shown to be linked to tumor cachexia in preclinical studies. The blockade of the transforming growth factor-beta (TGF-β) signaling pathway is able to ameliorate cachexia and survival in tumor-bearing mice, independent of inflammatory cytokines. Additionally, the authors are able to link the positive effects of prevention of cachexia to reduced cardiac wasting (Zhou et al., 2010).

**SECOND MESSENGERS MEDIATE METABOLIC CHANGES**

A direct link between cancer and cardiac function is found via circulating molecules. The heart as well as cancer cells release these factors or are affected by them, vice versa.

By cytokine release, the heart may function as an endocrine organ. Several mediators of cardiac origin have been found, which have an impact on metabolic regulations and tumor growth.

Myostatin, for example, is found to be released from the heart under failing conditions. This in turn promotes an inhibitory effect on muscle growth and may lead to muscle wasting. In cardiomyocyte-specific myostatin KO animals, wasting of the periphery muscles is attenuated after pressure-overload (Heineke et al., 2010).

Other factors—such as SerpinA1/3, Fibronectin, Ceruloplasmin, and Paraxonase 1—that are secreted from the heart, are found to be elevated in HF. Regarding SerpinA3, a direct influence on cancer cell growth is found. SerpinA3 is able to induce growth of colon cells and activates the protein kinase B signaling (Akt) pathway (Meijers et al., 2018). Akt signaling is essential in mediating glucose uptake and may inhibit pro-apoptotic factors (Nituulescu et al., 2018).

However, neoplastic cells in turn can release factors that affect metabolism and cardiac function. Insulin depletion, which can be mediated by tumors diseases, causes a decreased glucose uptake of the heart (a sign for a pathological metabolic switch) and is thereby a reason for cardiac muscle wasting. Insulin supplementation is able to attenuate the adverse effects on the heart (Thackeray et al., 2017). Ataxin-10 is another cachekoxine, that has been identified by an unbiased approach, which investigates the pro-atrophic secreted proteins of a certain colon cancer entity. Ataxin-10 causes cardiac metabolic alterations and muscle wasting (Schafer et al., 2016).

Recently, Karlstaedt et al. (2016) have found evidence for a metabolic messenger which is derived from cancer cells and is able to affect the cardiac metabolism, respectively. The authors characterize a mouse model for acute myeloid leukemia with an IDH2 mutation. The excreted metabolite D2-HG, which is
derived from the leukemic cells, alters glucose utilization and histone modifications in the heart. They mainly attribute these effects to an inhibition of the α-ketoglutarate dehydrogenase activity by D2-HG in the heart. These alterations are associated with cardiac remodeling (Karlstaedt et al., 2016). In cell culture, the oncometabolite 2-HG exacerbates doxorubicin mediates cardiotoxicity (Kattih et al., 2021).

There are still only few studies, investigating metabolomic alterations in patients plasma before, during or after oncolgical disease (Schmidt et al., 2021). However, in certain entities (e.g., pancreatic cancer) alterations of the metabolome are strongly associated with an increased risk to develop cancer (Mayers et al., 2014). If these alterations associate with an increased risk for cardiac complications, needs further evaluation.

Second messengers that may alter cancer and heart metabolism can also be of other origins. Myokines are cytokines which are released from the muscle (Manole et al., 2018). In cancer-induced cachexia, the levels of several myokines—including myostatin, IL-15, follistatin-related protein 1 (FSTL-1), fatty acid binding protein 3 (FABP3) and irisin—are elevated, suggesting that inhibition of myokines could be a therapeutical approach (de Castro et al., 2021).

Another group of circulating factors which influence cancer and the heart are microRNAs (miRs). MiR-145, for example, is found to be involved in the growth of many different tumors. It mainly functions as a tumor suppressor (Xing et al., 2018). MiR-145 also suppresses pathological remodeling in cardiovascular disease. Zhao et al. (2015) are able to link miR-145 to TGF-β signaling and to suppression of Angiotensin II-induced cardiac fibrosis. Other miRs, such as miR-1, miR-133, and miR-208, have been linked with cancer and cardiovascular diseases (Fichtlscherer et al., 2011; Mitchelson and Qin, 2015). Those miRs are elevated in the serum after ligation of the left anterior descending coronary artery in mice and after acute coronary syndrome (ACS) in patients (D’Alessandra et al., 2010; De Rosa et al., 2011). MiR-133a-1/2 dKO mice die due to developmental heart defects or, if they survive for at least six months, suffer from dilated cardiomyopathy. MiR-133-deficiency is linked to increased expression of the transcription factor (TF) serum response factor (SRF) (Liu et al., 2008). MiR-208a transgenic mice show alterations in the cardiac conduction system, e.g., atrioventricular blocks (Callis et al., 2009). In tumor cell lines, miR-1 and miR-133 are found to be tumor-suppressive, miR-208 in turn promotes tumor growth (Qin et al., 2013; Li et al., 2014; Liu et al., 2017).

### COMPARING THE METABOLIC SHIFT IN HEART FAILURE AND CANCER

Apart from studies of circulating metabolic factors that directly link cancer and the heart, comparable alterations in metabolism have been described in cardiac disease and cancer. These changes are summarized in Table 2.

In HF, there is a shift in metabolic substrate utilization to glucose. In the normal heart, ATP-production mainly relies on fatty acid oxidation (FAO). This phenomenon is termed metabolic remodeling (Tran and Wang, 2019).

Genetic deletion of RBPJ, a regulator of the NOTCH signaling pathway, leads to the disability of endothelial cells for fatty acid uptake in the muscle and heart. Consequently, FDG-PET/CT show a compensatory uptake of glucose in the heart. Mice that are deficient of RBPJ suffer from a reduced systolic ejection fraction, in line with elevated glucose-6-phosphat levels. A ketogenic diet is able to rescue this phenotype (Jabs et al., 2018). Metabolic remodeling is therefore not only a consequence of cardiac dysfunction but also causatively involved.

In pathological cardiac hypertrophy, due to pressure overload, the concurrent Akt signaling is mediating a decline in mitochondrial function and repression of FAO (Wende et al., 2015). Peroxisome proliferator-activated receptor-gamma coactivator (PGC-1α) regulates FAO and proteins involved in the electron transport chain. These factors are downregulated in HF. PGC-1α deficiency aggravates this process in response to pressure overload. Subsequently, the transition to HF is developing more rapidly (Arany et al., 2006). In LV hypertrophy, however, glycolysis rates are increased (Nascimben et al., 2004). Inhibiting phosphofructokinase (PFK), the rate-limiting enzyme, further aggravates HF after

| Table 2 | Regulation of metabolic genes in failing cardiomyocytes and cancer cells. |
|---------|--------------------------------------------------|
| Gene    | Failing cardiomyocyte                              | Cancer cell                                      |
| Akt     | • Akt is upregulated in the heart due to pressure-overload (Wende et al., 2015) | • Akt pathway activation is leading to cell growth (Sancho et al., 2015) |
|         | • Repression of FAO (Wende et al., 2015)           | • Akt enhances glucose supply via GLUT-1 and HK1 upregulation (Barthel et al., 1999; Majewski et al., 2004) |
| PGC-1α  | • Downregulation in heart failure (Arany et al., 2006) | • Upregulation in breast cancer increases glutamine flux and glycolysis rates via OGT/OGA (McGuirk et al., 2013) |
|         | • Inhibition deteriorates heart function during pressure-overload (Arany et al., 2006) | • PGC-1α positively regulates cellular respiration in the mitochondrion (Wu et al., 1999) |
| OGT/OGA (O-GlcNAc) | • Increased O-GlcNAc is protective in the diabetic heart (Marsh et al., 2011; Kroniage et al., 2019) | • Decreased O-GlcNAc induces apoptosis and reduces growth of breast cancer and pancreatic tumors (Caldwell et al., 2010; Ma et al., 2013; Ferrer et al., 2014) |
|         | • Inhibition of O-GlcNAc protects from pressure-overload (Umapathi et al., 2021) | |
| PFK     | • Inhibition deteriorates heart function during pressure-overload (Wang et al., 2013) | • Upregulation in cancer and maintenance of a high glycolytic flux, e.g., in leukemia cells (Chesney et al., 1999) |

FAO, Fatty acid oxidation; GLUT-1, Glucose transporter 1; HK, Hexokinase; PFK, Phosphofructokinase; PGC-1α, Peroxisome proliferator-activated receptor-gamma coactivator; Akt, Protein kinase B; O-GlcNAc, O-Linked N-Acetylglucosamine; OGT, Protein O-GlcNAc Transferase; OGA, protein O-GlcNAcase; TopoII, Topoisomerase II; VEGF, Vascular endothelial growth factor.
pressure overload (Wang et al., 2013). Apart from glycolysis, there are two other main pathways for glucose utilization: the pentose phosphate pathway (PPP) and the hexosamine biosynthesis pathway (HBP) (Tran and Wang, 2019). Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP, is a protective mechanism in response to oxidative stress. HBP-regulated effects are found to be protective or maladaptive, depending on the observed conditions (Jain et al., 2003). Enhanced O-GlcNAcylation via the HBP is found to mediate protective effects in the diabetic heart (Marsh et al., 2011). However, transgenic overexpression of OGT with a consequence of altered O-GlcNAcylation is sufficient to alter cardiac function, whereas inhibition of O-GlcNAcylation by overexpression of protein O-GlcNAcase (OGA) protects from pressure overload induced cardiac malfunction (Umapathi et al., 2021). One of the proteins which is regulated by O-GlcNAcylation and may in part mediate adverse effects is the Ca$^{2+}$-handling enzyme STIM1 (Lehmann et al., 2018). A regulating enzyme of the O-GlcNAcylation of STIM1, HDAC4, can be modified by O-GlcNAc itself. This phenomenon is identified to be a compensatory mechanism to prevent diabetes-associated HF (Kronlage et al., 2019). Given these data, metabolic disorders in FAO and glucose metabolism are part of a complex regulatory system and can be the cause as well as the consequence of HF.

In cancer, metabolism is principally shifting toward increased glucose utilization in response to a high demand of anabolic processes. Due to limited oxygen supply, this leads to high levels of lactate production. This phenomenon is known since the 1920s and named after his discoverer “Warburg” (Crabtree, 1928). Tumor suppressors and oncogenes are able to modulate the aerobic glycolysis of tumor cells and are thereby regulating tumor growth. P53 for example is able to downregulate the serine/threonine kinase Akt, is a major regulator in cancer-associated metabolism as well (Li et al., 2007; Bost and Kaminski, 2019). PGC-1α, a phosphorylation target of the serine/threonine kinase Akt, is a major regulator in cancer-associated metabolism as well (Li et al., 2007; Bost and Kaminski, 2019). PGC-1α is primarily responsible for maintaining the mitochondrial function including oxidative phosphorylation (Wu et al., 1999). This function is found to be intriguingly important in the survival of pancreatic cancer stem cells (Sancho et al., 2015). In breast cancer models, the Krebs cycle flux is dependent on PGC-1α, which itself depends on estrogen. In breast cancer patients, this metabolic activation is associated with a poor prognosis (McGuirk et al., 2013). Interestingly, cardiomyocyte-specific deletion of PGC-1α leads to peripartum-cardiomyopathy (PPCM), a hormone-sensitive cardiomyopathy in females after birth (Patten et al., 2012).

In prostate cancer, inhibition of PGC-1α reduces the androgen-receptor-dependent cell growth and might be used as a therapeutic approach (Shiota et al., 2010). The role of PGC-1α depends on the cancer type and the tissue-specific co-activating factor, such as the estrogen- or the androgen-receptor (Mastropasqua et al., 2018).

Increased flux in glycolysis is associated with tumor growth and upregulation of PFK (Chesney et al., 1999), but can occur in line with increased activity of the side-pathways, such as the HBP, as well. O-GlcNAcylation is a posttranslational modification which is linking metabolism to intracellular signaling in many tumor diseases (Ferrer et al., 2016). Exemplary, in breast cancer cell lines, the O-GlcNAcylated and the regulating enzyme, O-GlcNac transferase (OGT), are found to regulate the transcription factor HIFα and thereby GLUT-1 expression. Reduction of global O-GlcNAcylation leads to the induction of apoptosis (Ferrer et al., 2014). In breast cancer xenograft models with OGT deficiency, the tumor growth is reduced (Caldwell et al., 2010). In pancreas cancer cell lines, reduction of O-GlcNAcylation leads to the apoptosis as well. This effect is attributed to the transcription factor NFkB (Ma et al., 2013). Taken together, O-GlcNAcylation seems to be a central regulator in many tumor diseases, which can be used as a therapeutic target in cancer. In parallel, it plays an important role in cardiac function and dysregulation results in maladaptive response.

### CARDIAC METABOLIC CONSEQUENCES OF CANCER THERAPIES

The common metabolic alterations and signaling pathways in the heart and cancer might be influenced by cancer therapies as well (Table 3). Antiangiogenic drugs, for example, have been a milestone in the therapy of many progressed tumor diseases. Bevacizumab is the first vascular endothelial growth factor (VEGF) signaling pathway inhibitor to be approved by the FDA. It dramatically improves the progression-free survival of many tumor entities, such as colorectal carcinoma (McCormack and Keam, 2008). Tyrosine kinase inhibitors, also

| Group of drugs | Molecular target | Metabolic alterations in the heart |
|----------------|-----------------|----------------------------------|
| VEGF inhibitors, e.g., Bevacizumab and tyrosine kinase inhibitors | GLUT-1 (Giordano et al., 2001, PGC-1α (Kivi et al., 2014), Akt (Kivi et al., 2014; Pandey et al., 2018)) | * Arterial hypertension (Pandey et al., 2018) * Shift from FAO to glucose uptake in cardiomyocytes (Kivi et al., 2014) |
| Anthracyclines, e.g., doxorubicin | TopoIIβ (Zhang et al., 2012, PGC-1α (Zhang et al., 2012), IL-6 (Elsea et al., 2015)) | * Increased apoptosis (Elsea et al., 2015; Willis et al., 2019) * Cachexia (Elsea et al., 2015; Willis et al., 2019) * Mitochondrial dysfunction (Elsea et al., 2015) |

| Metabolic alterations | 
|----------------------|
| FAO, Fatty acid oxidation; GLUT-1, Glucose transporter 1; IL, Interleukin; PGC-1α, Peroxisome proliferator-activated receptor-gamma coactivator; Akt, Protein kinase B; TopoIIβ, Topoisomerase IIIβ; VEGF, Vascular endothelial growth factor. |
inhibiting angiogenesis and VEGF signaling, further improve cancer therapy (Shawver et al., 2002; Huang et al., 2020).

A cardiomyocyte-specific KO mouse of VEGF shows reduced microvasculature, reduced ejection fraction and the induction of hypoxia-induced genes, including GLUT-1 (Giordano et al., 2001). In VEGF transgenic rats, there is a hypervascularization of the heart and a metabolic shift from FAO to glucose metabolism. Among others, those changes are linked to an altered expression of PGC-1α and an activation of the Akt-signaling pathway (Kivela et al., 2014). Thus, angiogenesis inhibitors may contribute to cardiotoxic and specifically metabolic alterations. Commonly, arterial hypertension is a known adverse effect of VEGF inhibitors. This in turn may activate kinases, such as Akt (Pandey et al., 2018).

Anthracyclines, e.g., doxorubicin, have been used for cancer therapy for over 60 years and still are included in standard chemotherapy regimens (Rivankar, 2014). Cardiotoxic effects of doxorubicin depend on topoisomerase IIβ (TopoIIβ), which is shown in TopoIIβ KO mice. Interestingly, one of the downstream targets of this TopoIIβ-dependent effect is PGC-1α (Zhang et al., 2012). The animals show structural changes of the mitochondria, indicating a similar metabolic change compared to primary HF. A doxorubicin-containing chemotherapy induces IL-6 release in non-tumor bearing mice and is associated with loss of lean body mass, comparable to other IL-6 tumor models (Elsea et al., 2015).

Data from patients support the notion of a pro-atrophic effect of anthracyclines (Willis et al., 2019).

**DISCUSSION AND CONCLUSION**

Cancer and cardiovascular diseases are two major burdens in the treatment of an increasing number of patients. In this review, we focus on the interaction of both diseases and their relation to metabolic alterations. Both, cancer and HF, are associated with malnutrition and cachexia. A significantly increased mortality is the clinical consequence of these important co-morbidities.

Looking at different preclinical studies, we observe multiple factors which are influencing tumor growth, cachexia, HF and intracellular substrate utilization. The mediators are summarized in Table 1. Inflammation and especially cytokines, possibly derived from malignant or cardiovascular diseases, are important mediators of muscle atrophy. Other primary non-inflammatory cytokines can be excreted from the heart, such as myostatin or SerpinA3, or from the tumor, such as Ataxin-10. These cytokines can lead to either tumor growth or wasting. Besides, several miRs (miR-1, miR-133, miR-145, miR-208) are linked to cardiac remodeling and tumor growth. In addition, FAO- and glycolysis-regulating enzymes, e.g., PGC-1α, HK-1, GLUT-1, as well as side
pathways of glycolysis (PPP, HBP) are linked to HF and tumor growth, respectively (Figure 1).

These studies suggest many concurrent molecular alterations of both diseases, which might explain the co-occurrence of these diseases. Further, cancer therapies, e.g., angiogenesis inhibitors and anthracyclines, may also intervene at the same intracellular metabolic targets.

Future oncological and cardiological therapies should keep these interdisciplinary effects in mind, in order to minimize adverse effects and reduce mortality and morbidity.

The knowledge of the specific molecular alterations may lead to personalized treatment options in cancer therapies and to personalized cardiac surveillance protocols, according to cancer type and previous metabolomic profiles.

REFERENCES

Anker, S. D., Egerer, K. R., Volk, H. D., Kox, W. J., Poole-Wilson, P. A., and Coats, A. J. (1997a). Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am. J. Cardiol. 79, 1426–1430. doi: 10.1016/s0002-9149(97)00159-8

Anker, S. D., Pomikowski, P., Varney, S., Chua, T. P., Clark, A. L., Webb-Peploe, K. M., et al. (1997b). Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050–1053.

Anker, S. D., and von Haehling, S. (2004). Inflammatory mediators in chronic heart failure: an overview. Heart 90, 464–470. doi: 10.1136/hrt.2002.007005

Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., and Takabe, K. (2015). Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. 7, 17–29. doi: 10.42531/wjgo.v7.i14.17

Arany, Z., Novikov, M., Chin, S., Ma, Y., Rosenzweig, A., and Spiegelman, B. M. (2006). Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc. Natl. Acad. Sci. U. S. A. 103, 10086–10091. doi: 10.1073/pnas.0603615103

Argiles, J. M., Busquets, S., Stemmler, B., and Lopez-Soriano, F. J. (2014). Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754–762. doi: 10.1038/nrc3829

Bang, C., Antoniades, C., Antonopoulos, A. S., Eriksson, U., Franssen, C., Hamdani, N., et al. (2015). Intercellular communication lessons in heart failure. Eur. J. Heart Fail. 17, 1091–1103.

Barkhudaryan, A., Scherbakov, N., Springer, J., and Doehner, W. (2017). Cardiac metabolism in cancer: new insights into the metabolic adaptations of cancer cells and their microenvironment. J. Biol. Chem. 274, 20281–20286.

Bird, B. R., and Swain, S. M. (2008). Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin. Cancer Res. 14, 14–24.

Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., et al. (2012). JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303, E410–E421. doi: 110.1152/ajpendo.00039.2012

Bost, F., and Kaminski, L. (2019). The metabolic modulator PGC-1alpha in cancer. Am. J. Clin. Nutrition 109, 13076–13081. doi: 10.1073/pnas.1200419109

Cardinale, D. (1996). [A new frontier: cardio-oncology]. Cardiologia 41, 887–891.

Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., et al. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131, 1981–1988. doi: 10.1161/circulationaha.114.013777

Chan, J. S., Tan, M. J., Sng, M. K., Teo, Z., Phua, T., Choo, C. C., et al. (2017). Cancer-associated fibroblasts enact field cancerization by promoting extratumoral oxidative stress. Cell Death Dis. 8x2562. doi: 10.1038/cddis.2016.492

Chesney, J., Mitchell, R., Benigni, F., Racher, M., Spiegel, L., Al-Abed, Y., et al. (1999). An inducible product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc. Natl. Acad. Sci. U. S. A. 96, 3047–3052. doi: 10.1073/pnas.96.6.3047

Clunton, A. A., Lukey, M. J., Cerione, R. A., and Locasale, J. W. (2017). Glutamine Metabolism in Cancer: understanding the Heterogeneity. Trends Cancer 3, 169–180. doi: 10.1016/j.trecan.2017.01.005

Crabtree, H. G. (1928). The carbohydrate metabolism of certain pathological overgrowths. Biochem. J. 22, 1289–1298.

D’Alessandra, Y., Devanna, P., Limana, F., Straino, S., Carlo, A. Di, Pambilla, P. B., et al. (2010). Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart J. 31, 2765–2773.

de Castro, G. S., Correia-Lima, J., Simoes, E., Orsos, C. E., Xiao, J., Gama, L. R., et al. (2021). Myokines in treatment-naive patients with cancer-associated cachexia. Clin. Nutr. 40, 2434–2455. doi: 10.1016/j.clnu.2020.10.050

De Rosa, S., Fichtlscherer, S., Lehmann, R., Assmus, B., Dimmeler, S., and Zeiher, A. M. (2011). Transcoronary concentration gradients of circulating microRNAs. Circulation 124, 1936–1944.

Demers, M., Krause, D. S., Schatzberg, K., Martinod, K., Voorhees, J. R., Fuchs, T. A., et al. (2012). Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. U. S. A. 109, 13076–13081. doi: 10.1073/pnas.120419109

Duan, Z., and Luo, Y. (2021). Targeting macropheages in cancer immunotherapy. Signal. Transduct. Target. Ther. 6:127.

Elsea, C. R., Kneiss, J. A., and Wood, L. J. (2015). Induction of IL-6 by Cytotoxic Chemotherapy Is Associated With Loss of Lean Body and Fat Mass in Tumor-free Female Mice. Biol. Res. Nurs. 17, 549–557. doi: 10.1177/109980041558087

Fearon, K. C., Voss, A. C., Hustead, D. S., and Cancer Cachexia Study Group (2006). Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 83, 1345–1350. doi: 10.1093/ajcn/83.6.1345

Ferrer, C. M., Lynch, T. P., Sodi, V. L., Falcone, J. N., Schwab, L. D., Peacock, D. L., et al. (2014). O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol. Cell 54, 820–831. doi: 10.1016/j.molcel.2014.04.026

Ferrer, C. M., Sodi, V. L., and Reginato, M. J. (2016). O-GlcNAcylation in Cancer Biology: linking metabolism and signaling. J. Mol. Biol. 428, 3282–3294. doi: 10.1016/j.jmb.2016.05.028

AUTHOR CONTRIBUTIONS

DF, MH, NF, and LHL contributed to the conception and design of the review. DF wrote the first draft of the manuscript. DF and LHL wrote sections of the manuscript. All authors contributed to manuscript revision and approved the submitted version.

FUNDING

LHL received grants from the German Center for Cardiovascular Research (DZHK), German Research Foundation (DFG) LE3570/2-1; 3570/3-1 and grant 01KC2006B from the Federal Ministry for Education and Research (BMBF).
Fichtlscherer, S., Zeiher, A. M., and Dimmeler, S. (2011). Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler. Thromb. Vasc. Biol. 31, 2383–2390. doi: 10.1161/ATVHA.111.226696
Finke, D., Romann, S. W., Beckmann, M. B., Hund, H., Bougatf, N., Kantharajah, A., et al. (2021). High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: a single-centre cohort study. ESC Heart Fail. 8, 3709–3719. doi: 10.1002/ehf2.13155
Franz, S., and Nahrendorf, M. (2014). Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc. Res. 102, 240–248. doi: 10.1093/cvr/cvu025
Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A., and Abnet, C. C. (2011). Association between smoking and risk of bladder cancer among men and women. JAMA 306, 737–745.
Gernaert, S. A. M., Boer, J. M. A., van den Bongard, D. H. J., Maas, A., van der Pol, C. C., Bijlsma, R. M., et al. (2018). The risk of cardiovascular disease following breast cancer by Framingham risk score. Breast Cancer Res. Treat. 170, 119–127.
Giordano, F. J., Gerber, H. P., Williams, S. P., VanBruggen, N., Bunting, S., Ruiz-Ortega, M., et al. (2018). Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 121, 419–425. doi: 10.1161/CIRCULATIONAHA.109.882068
Huang, L., Jiang, S., and Shi, Y. (2020). Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J. Hematol. Oncol. 13:143. doi: 10.1186/s13045-020-00977-0
Jabs, M., Rose, A. J., Lehmann, L. H., Taylor, J., Moll, I., Sijmonsma, T. P., et al. (2018). Inhibition of Endothelial Notch Signaling Impairs Fatty Acid Transport and Leads to Metabolic and Vascular Remodeling of the Adult Heart. Circulation 137, 2592–2608. doi: 10.1161/CIRCULATIONAHA.117.029733
Jacoby, D., and McKenna, W. J. (2012). Genetics of inherited cardiomyopathy. Eur. Heart J. 33, 296–304. doi: 10.1093/euheartj/ehr260
Jain, M., Brenner, D. A., Cui, L., Lim, C. C., Wang, B., Pimentel, D. R., et al. (2003). Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ. Res. 93, e9–e16. doi: 10.1161/01.RES.0000083489.83704.76
Kanai, A. J., Stewart, S. S., Suescun, C., Astorga, J., Sorensen, Z. H., et al. (2017). Identification of a neuronal nitric oxide synthase in isolated heart myocytes. PLoS One 12, e0184701.
Karlstaedt, A., Schiffer, W., and Taegtmeyer, H. (2018). Actionable metabolic innate immune reprogramming. J. Immunol. Res. 2018, 33, 1104–1114. doi: 10.1155/2018/8260742
Koene, R. J., Prinzen, A. E., Blaes, A., and Konety, S. H. (2016). Shared risk factors in cardiovascular disease and cancer. Circulation 133, 1104–1114. doi: 10.1161/circulationaha.115.020406
Kondoh, H., Leonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., et al. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Res. 65, 177–185.
Kronek, M., Dewerenter, M., Grosso, J., Fleming, T., Oehl, U., Lehmann, L. H., et al. (2019). O-GlcNAcylation of histone deacetylase 4 protects the diabetic heart from failure. Circulation 140, 580–594. doi: 10.1161/CIRCULATIONAHA.117.031942
Laird, B. J., McMillan, D., Skipworth, R. J. E., Fallon, M. T., Paval, D. R., McNeish, I., et al. (2021). The Emerging Role of Interleukin 1beta (IL-1beta) in Cancer Cachexia. Inflammation. Inflammation 44, 1223–1228. doi: 10.1007/s10753-021-01429-8
Levits, B. E., Binkley, P. F., and Shapiro, C. L. (2017). Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. 18, e445–e456. doi: 10.1016/S1470-2045(17)30353-1
Li, H., Zheng, D., Zhang, B., Liu, L., Ou, J., Chen, W., et al. (2014). Mir-208b regulates abundance of cardiac speciality proteins by targeting miR-375. J. Hematol. Oncol. 7:143. doi: 10.1186/s13045-014-0120-1
Liu, N., Bezprozvannaya, S., Williams, A. H., Qi, X., Richardson, J. E., and Reed, M. B. (1998). Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 12, 871–880. doi: 10.1096/fasebj.12.10.971
Li, C., Zhang, S., Wang, Q., and Zhang, X. (2017). Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes. Oncotarget 8, 42043–42060. doi: 10.18632/oncotarget.14927
Li, D., Ma, Z., Yang, J., Zhao, M., Ao, H., Zheng, X., et al. (2019). Predictive and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY) 11, 7948–7960. doi: 10.18632/aging.102301
Liu, N., Pezзованфяйма, С., Williams, A. H., Qi, X., Richardson, J. A., Bassel-Duby, R., et al. (2008). microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22, 3242–3254. doi: 10.1101/gad.1738708
Lopez-Sendon, J., Alvarez-Ortega, C., Zamora Aunon, P., Rono Soto, A., Lyon, A. R., Farmakidis, D., et al. (2020). Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur. Heart J. 41, 1720–1729. doi: 10.1093/eurheartj/ehaa006
Ma, Z., Vocadlo, D. J., and Vosseller, K. (2013). Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J. Proteome Res. 12, 7948–7960. doi: 10.1021/pr300721z
Manole, E., Ceafalan, L. C., Popescu, B. O., Dumitru, C., and Bastian, A. E. (2018). Myokinase as possible therapeutic targets in cancer cachexia. J. Immunol. Res. 2018, 33, 1104–1114. doi: 10.1155/2018/8260742
Pavlova, N. N., and Thompson, C. B. (2016). The Emerging Hallmarks of Cancer Metabolism. *Cell Metab.* 23, 27–47. doi: 10.1016/j.cmet.2015.12.006

Pavo, N., Raderer, M., Hulsmann, M., Neuhold, S., Adlbrecht, C., Strunk, G., et al. (2015). Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. *Heart* 101, 1874–1880.

Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., et al. (2016). European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur. J. Prev. Cardiol.* 23, N1–N96.

Qin, Y., Dang, X., Li, W., and Ma, Q. (2013). miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. *Oncol. Res.* 21, 353–363. doi: 10.3726/096504114X1424160459122

Quail, D. F., and Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. *Nat. Med.* 19, 1423–1437. doi: 10.1038/nm.3394

Rassaf, T., Totzeck, M., Backs, J., Bokemeyer, C., Hallek, M., Hilfinger-Kleiner, D., et al. (2009). Onco-cardiology: consensus paper of the german cardiac society, the german society for pediatric cardiology and congenital heart defects and the german society for hematology and medical oncology. *Clin. Res. Cardiol.* 109, 1197–1222. doi: 10.1007/s00392-010-01636-7

Rathmell, J. C., Fox, C. J., Plas, D. R., Hammerman, P. S., Cinalli, R. M., and Thompson, C. B. (2003). Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. *Mol. Cell Biol.* 23, 7315–7328. doi: 10.1128/MCB.23.20.7315-7328.2003

Rinde, L. B., Smalbrekke, K., Hald, E. M., Brodin, E. E., Njeldstad, I., Mathiesen, E. B., et al. (2017). Myocardial infarction and future risk of cancer in the general population—the Tromsø Study. *Eur. J. Epidemiol.* 32, 193–201. doi: 10.1007/s10654-017-0231-5

Rivankan, S. (2014). An overview of doxorubicin formulations in cancer therapy. *J. Cancer Res. Ther.* 10, 853–858. doi: 10.4103/0973-1482.139267

Sancho, P., Burgos-Ramos, E., Tavera, A., Kheir, T., Bou, Jagust, P., Schoenhals, M., et al. (2015). MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. *Cell Metab.* 22, 590–605. doi: 10.1016/j.cmet.2015.08.015

Schafer, M., Oeing, C. U., Rohm, M., Bayal-Temel, E., Lehmann, L. H., Bauer, R., et al. (2016). Ataxin-10 is part of a cachexia cocktail triggering cancer metabolic dysfunction in cancer cachexia. *Mol. Metab.* 5, 67–78. doi: 10.1016/j.molmet.2015.11.004

Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., and Locasale, J. W. (2011). Metabolomics in cancer research and emerging applications in clinical oncology. *CA Cancer J. Clin.* 71, 333–358. doi: 10.3322/caac.21670

Seferovic, P. M., and Paulus, W. J. (2015). Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. *Eur. Heart J.* 36, 1718–1727. doi: 10.1093/eurheartj/ehv134

Serrano, J. M., Gonzalez, I., Del Castillo, S., Muniz, J., Morales, L. J., Serrano, J. M., et al. (2014). Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. *Eur. J. Cancer* 50, 1193–1198. doi: 10.1016/j.ejca.2014.03.004

Shock, W., Bajamonde, A., Shak, S., Fuchs, H., Paton, V., LeMaire, C., et al. (1998). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N. Engl. J. Med.* 339, 1197–1222. doi: 10.1056/nejm199808273391401

Smith, I. M., and Eisinger, P. (2011). The complex effect of hypoxia on cancer cell proliferation. *Cell Mol. Life Sci.* 68, 487–506. doi: 10.1007/s00018-010-0168-z

Springer, J., Tischirner, A., Haghikia, A., von Haehling, S., Lal, H., Grzesiak, A., et al. (2014). Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. *Eur. Heart J.* 35, 932–941. doi: 10.1093/eurheartj/ehu302

Stålau-van den Brekel, A. J., Dentener, M. A., Schofs, A. M., Bouwman, W. A., and Wouters, E. F. (1995). Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. *J. Clin. Oncol.* 13, 2600–2605. doi: 10.1200/JCO.1995.13.10.2600

Noy, R., and Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. *Immunity* 41, 49–61. doi: 10.1016/j.immuni.2014.06.010

Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., et al. (1987). Tumors secreting human TNF/cachectin induce cachexia in mice. *Cell* 50, 555–563. doi: 10.1016/0022-802X(87)90208-6

Olson, C. O., Quail, D. F., and Joyce, J. A. (2017). Obesity and the tumor microenvironment. *Science* 358, 1130–1131.

Ozcêlîk, Ç., Erdmann, B., Pülz, B., Wettenschweck, N., Britsch, S., Hubner, N., et al. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. *Proc. Natl. Acad. Sci. U. S. A.* 99, 8880–8885. doi: 10.1073/pnas.122249299

Pandey, A. K., Singh, E. K., Arroyo, J. P., Ikizler, T. A., Gould, E. R., Brown, J., et al. (2018). Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. *Hypertension* 71, e1–e8. doi: 10.1161/HYPERTENSIONAHA.117.10271

Pasi, E., Aquilani, R., Testa, C., Biaardi, P., Angioletti, S., Boschi, F., et al. (2016). Pathogenic gut flora in patients with chronic heart failure. *JACC Heart Fail.* 4, 220–227. doi: 10.1016/j.jchf.2015.10.009

Patten, I. S., Rana, S., Shahul, S., Rowe, G. C., Jiang, C., Liu, L., et al. (2012). Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. *Nature* 485, 333–338. doi: 10.1038/nature11040

Paulin, K. C., and Kiefer, D. (2016). The Emerging Hallmarks of Cancer Metabolism. *Cell Metab.* 23, 27–47. doi: 10.1016/j.cmet.2015.12.006
Steffen, B. T., Lees, S. J., and Booth, F. W. (2008). Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. J. Appl. Physiol. 105, 1950–1958. doi: 10.1152/japplphysiol.00884.2008

Stocks, T., Hemelrijck, M., Van, Manjer, J., Bjorge, T., Ulmer, H., Hallmans, G., et al. (2012). Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 59, 802–810. doi: 10.1161/hypertensionaha.11.189258

Strassburg, S., Springer, J., and Anker, S. D. (2005). Muscle wasting in cardiac cachexia. Int. J. Biochem. Cell Biol. 37, 1938–1947.

Strassmann, G., Fong, M., Kenney, J. S., and Jacob, C. O. (1992). Evidence for the involvement of interleukin 6 in experimental cardiac cachexia. J. Clin. Invest. 89, 1681–1684. doi: 10.1172/jci115767

Strassmann, G., Masui, Y., Chizzonite, R., and Fong, M. (1993). Mechanisms of experimental cardiac cachexia. Local involvement of IL-1 in colon-26 tumor. J. Immunol. 150, 2341–2345.

Sturgeon, K. M., Deng, L., Blautmann, S. M., Zhou, S., Trifiletti, D. M., Jiang, C., et al. (2019). A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur. Heart J. 40, 3889–3897. doi: 10.1093/eurheartj/ehz766

Tang, W. H. W., Li, D. Y., and Hazen, S. L. (2019). Dietary metabolism, the gut microbiome, and heart failure. Nat. Rev. Cardiol. 16, 137–154. doi: 10.1038/s41569-018-01018-7

Thackeray, J. T., Pietzsch, S., Stapel, B., Ricie-Hoch, M., Lee, C. W., Bankstahl, J. P., et al. (2017). Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. JCI Insight 2:e93098. doi: 10.1172/jci.insight.93098

Tilemann, L. M., Heckmann, M. B., Katus, H. A., Lehmann, L. H., and Muller, O. J. (2018). Cardio-ontology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin. Res. Cardiol. 107, 271–280. doi: 10.1007/s00392-018-1202-x

Tran, D. H., and Wang, Z. V. (2019). Glucose Metabolism in Cardiac Hypertrophy and Heart Failure. J. Am. Heart Assoc. 8:e012673.

Tsujinaka, T., Ebisui, C., Fujita, J., Kishibuchi, M., Morimoto, T., Ogawa, A., et al. (1995). Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem. Biophys. Res. Commun. 207, 168–174. doi: 10.1006/bbrc.1995.1168

Umapathi, P., Mesubi, O. O., Banerjee, P. S., Abrol, N., Wang, Q., Luczak, E. D., et al. (2021). Excessive O-GlcNAcylation causes heart failure and sudden death. Circulation 143, 1687–1703. doi: 10.1161/circulationaHA.120.051911

van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., et al. (2008). Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43–51. doi: 10.1161/circulationaHA.107.728550

von Haehling, S., and Anker, S. D. (2014). Prevalence, incidence and cardiac impact of cachexia: facts and numbers-update 2014. J. Cachexia Sarcopenia Muscle 5, 261–263. doi: 10.1007/s13359-014-0164-8

von Haehling, S., Doehner, W., and Anker, S. D. (2007). Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res. 73, 298–309. doi: 10.1016/j.cardiores.2006.08.018

Wang, J., Xu, J., Wang, Q., Brainard, R. E., Watson, L. J., Jones, S. P., et al. (2013). Reduced cardiac fructose 2,6 bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction. PLoS One 8:e53951. doi: 10.1371/journal.pone.0053951

Wende, A. R., O’Neill, B. T., Bugger, H., Riehle, C., Tuinei, J., Buchanan, J., et al. (2015). Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes. Mol. Cell Biol. 35, 831–846. doi: 10.1128/MCB.01109-14

Willis, M. S., Parry, T. L., Brown, D. I., Mota, R. I., Huang, W., Beak, J. Y., et al. (2019). Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1. Circ. Heart Fail. 12:e005234. doi: 10.1161/CIRCHEARTFAILURE.118.005234

Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., et al. (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115–124. doi: 10.1016/S0092-8674(00)08011-X

Xia, H., Yamada, S., Aoyama, M., Sato, F., Masaki, A., Ge, Y., et al. (2014). Prognostic impact of microRNA-145 down-regulation in adult T-cell leukemia/lymphoma. Hum. Pathol. 45, 1192–1198. doi: 10.1016/j.humpath.2014.01.017

Xing, A. Y., Wang, B., Shi, D. B., Zhang, X. F., Gao, C., He, X. Q., et al. (2013). Dereguled expression of miR-145 in manifold human cancer cells. Exp. Mol. Pathol. 95, 91–97. doi: 10.1016/j.yexmp.2013.05.003

Zambetti, M., Moliterni, A., Materazzo, C., Stefanelli, M., Cipriani, S., Valagussa, P., et al. (2001). Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol. 19, 37–43. doi: 10.1200/jco.2001.19.1.37

Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., et al. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639–1642. doi: 10.1038/nm.2919

Zhao, N., Koenig, S. N., Trask, A. J., Lin, C. H., Hans, C. P., Garg, V., et al. (2015). MicroRNA miR145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. Circ. Res. 116, 23–34. doi: 10.1161/CIRCRESAHA.115.303970

Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., et al. (2010). Reversal of cardiac cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531–543. doi: 10.1016/j.cell.2010.07.011

Conflict of Interest: IHL has served on the advisory board for Daiichi Sankyo, Senaca, and Servier, as well as an external expert for Astra Zeneca and received speakers’ honoraria from Novartis and MSD.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Finke, Heckmann, Frey and Lehmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.